^
    1d
    Lung-Map Sub-Study: Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (clinicaltrials.gov)
    P3, N=275, Active, not recruiting, SWOG Cancer Research Network | Trial completion date: Apr 2026 --> Apr 2027
    Trial completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    1d
    Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, West China Hospital
    New P2 trial
    |
    Focus V (anlotinib) • Kaitanni (cadonilimab)
    1d
    QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P2/3, N=120, Not yet recruiting, Sun Yat-sen University
    New P2/3 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Focus V (anlotinib) • Qibeian (iparomlimab/tuvonralimab)
    1d
    eVOLVE-Meso: MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (clinicaltrials.gov)
    P3, N=861, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2027 --> Nov 2028
    Enrollment closed • Trial primary completion date
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • pemetrexed • volrustomig (MEDI5752)
    2d
    Pathological Complete Response to Nivolumab Plus Ipilimumab Combination Therapy in Advanced Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus. (PubMed, IJU Case Rep)
    Histopathological examination following radical nephrectomy with tumor thrombectomy demonstrated a pathological complete response. Diffuse programmed death-ligand 1 expression on pretreatment biopsy may have been associated with a favorable response to nivolumab plus ipilimumab.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    2d
    Significant Response to Nivolumab Plus Ipilimumab in Metastatic Mucinous Tubular and Spindle Cell Carcinoma: A Case Report. (PubMed, IJU Case Rep)
    No disease progression was observed at 9 months. This case demonstrates the potential efficacy of combination immunotherapy in aggressive metastatic MTSCC.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden)
    |
    TMB-L
    |
    FoundationOne® CDx
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    2d
    Autopsy-Proven Immune-Mediated Hepatitis With Rapid Liver Atrophy Despite Minimal Aminotransferase Elevation After Durvalumab Plus Tremelimumab Therapy for Hepatocellular Carcinoma: A Case Report. (PubMed, Clin Case Rep)
    The tumor burden was small without metastasis. This case highlights that ICI hepatitis can progress with minimal aminotransferase elevation in advanced cirrhosis, warranting multidimensional monitoring beyond aspartate aminotransferase/alanine aminotransferase, including bilirubin, coagulation parameters, clinical decompensation, and quantitative imaging.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    2d
    A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Aug 2026 --> Aug 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    5d
    A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov)
    P2, N=37, Recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 amplification • HER-2 negative
    |
    Kaitanni (cadonilimab)
    5d
    Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Abramson Cancer Center at Penn Medicine | Initiation date: Apr 2026 --> Sep 2026
    Trial initiation date
    |
    docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • sturlimogene erparepvec (RP2)
    5d
    VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=18, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar) • Voyager-V1
    5d
    Blue nevus-like melanoma: A rare entity. (PubMed, Dermatol Online J)
    Despite 4 cycles of ipilimumab/nivolumab immunotherapy, the disease progressed, and the patient died 4 months after diagnosis. BNM is a rare melanoma variant, often arising from a pre-existing blue nevus, with aggressive potential and frequent lymph node metastasis. The molecular heterogeneity of BNM and the limited therapeutic options underscore the need for further research into targeted therapies and prognostic biomarkers for this rare melanoma subtype.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • SOX10 (SRY-Box 10) • PRAME (Preferentially Expressed Antigen In Melanoma) • MLANA (Melan-A)
    |
    BRAF mutation • BRAF V600
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)